Abstract: The present disclosure relates to a ULBP6 binding protein that inhibits the interaction between ULBP6 and NKG2D, and methods of treating cancer with said ULBP6 binding protein.

Abstract: The present disclosure provides a package structure. The package structure includes a die bonding region and a first lead region. The first lead region extends along a first direction. The first direction is along a first edge of the die bonding region. The first lead region includes a first high density lead region and a first low density lead region. The first high density lead region overlaps the first low density lead region in the first direction.

Abstract: An electronic device includes a substrate; and a coil structure disposed on the substrate. The coil structure is provided with a first conductor layer including a connection line; a second conductor layer including a plurality of line segments separated from each other; and a first insulation layer disposed between the first conductor layer and the second conductor layer, and provided with a plurality of first openings, wherein adjacent two of the plurality of line segments are electrically connected to the connection line through the plurality of first openings.

Abstract: Compounds of formula (I): wherein A1, A2, Ra, Rb, Rc, Rd, R3, R4, R5 and T are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

Abstract: A method and device are disclosed from the perspective of a first Wireless Transmit/Receive Unit (WTRU). In one embodiment, the method includes the first WTRU triggering a first buffer status report (BSR), wherein the first BSR indicates an amount of data expected to arrive. The method also includes the first WTRU triggering a second BSR, wherein the second BSR indicates an amount of data already available. The method further includes the first WTRU generating a MAC (Medium Access Control) PDU (Protocol Data Unit), wherein the MAC PDU includes at most one first BSR MAC CE (Control Element) for the first BSR and at most one second BSR MAC CE for the second BSR.

Abstract: Compound of formula (I): wherein A1, A2, Ra, Rb, Rc, Rd, R3, R4, X, Y and G are as defined in the description, and their use in the manufacture of medicaments.

Abstract: Methods and devices are disclosed from the perspective of a first wireless transmit/receive unit (WTRU). In one method, the method includes triggering a first buffer status report (BSR), wherein the first BSR indicates an estimated amount of data expected to arrive.

Abstract: Methods and apparatuses are provided to avoid unintended UE state transition, and the risk of packet loss due to unintended UE state transition is reduced. The methods and apparatuses are also provided to avoid unintended BWP switching, and the risk of packet loss due to unintended BWP switching is reduced. A device (e.g., UE) is configured by a network node with at least a serving cell and the serving cell is configured with one or multiple bandwidth parts (BWPs) and a timer. The device monitors and receives an information from physical downlink control channel (PDCCH) on an active BWP, wherein the PDCCH is addressed to a group-common RNTI (GC-RNTI) used for multicast or broadcast service (MBS), and wherein the information indicates downlink assignment on the active BWP and the device starts or restarts the timer.

Abstract: Methods and apparatuses are provided to avoid unintended UE state transition, and the risk of packet loss due to unintended UE state transition is reduced. The methods and apparatuses are also provided to avoid unintended BWP switching, and the risk of packet loss due to unintended BWP switching is reduced. A device (e.g., UE) is configured by a network node through a signaling with a functionality, wherein the functionality is associated with a timer. The device receives a package, wherein the package contains one or more payload, and the payload is mapped to a logical channel, wherein the logical channel is used for multicast and/or broadcast service, and the device starts or restarts the timer.

Abstract: Methods and apparatuses are provided to avoid unintended UE state transition, and the risk of packet loss due to unintended UE state transition is reduced. The methods and apparatuses are also provided to avoid unintended BWP switching, and the risk of packet loss due to unintended BWP switching is reduced. A device (e.g., UE) is configured by a network node through a signaling with a functionality, wherein the functionality is associated with a timer. The device receives a package, wherein the package contains one or more payload, and the payload is mapped to a logical channel, wherein the logical channel is used for multicast and/or broadcast service, and the device starts or restarts the timer.

Abstract: A method and device are disclosed from the perspective of a first Wireless Transmit/Receive Unit (WTRU). In one embodiment, the method includes the first WTRU triggering a first buffer status report (BSR), wherein the first BSR indicates an amount of data expected to arrive. The method also includes the first WTRU triggering a second BSR, wherein the second BSR indicates an amount of data already available. The method further includes the first WTRU generating a MAC (Medium Access Control) PDU (Protocol Data Unit), wherein the MAC PDU includes at most one first BSR MAC CE (Control Element) for the first BSR and at most one second BSR MAC CE for the second BSR.

Abstract: wherein A1, A2, R3, Rb, Rc, Rd, R3, R4, R5 and T are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

Abstract: A method and device are disclosed from the perspective of a first Wireless Transmit/Receive Unit (WTRU). In one embodiment, the method includes the first WTRU triggering a first buffer status report (BSR), wherein the first BSR indicates an amount of data expected to arrive. The method also includes the first WTRU triggering a second BSR, wherein the second BSR indicates an amount of data already available. The method further includes the first WTRU generating a MAC (Medium Access Control) PDU (Protocol Data Unit), wherein the MAC PDU includes at most one first BSR MAC CE (Control Element) for the first BSR and at most one second BSR MAC CE for the second BSR.

Abstract: A method and device are disclosed from the perspective of a first Wireless Transmit/Receive Unit (WTRU). In one embodiment, the method includes the first WTRU triggering a first buffer status report (BSR), wherein the first BSR indicates an amount of data expected to arrive. The method also includes the first WTRU triggering a second BSR, wherein the second BSR indicates an amount of data already available. The method further includes the first WTRU generating a MAC (Medium Access Control) PDU (Protocol Data Unit), wherein the MAC PDU includes at most one first BSR MAC CE (Control Element) for the first BSR and at most one second BSR MAC CE for the second BSR.

Abstract: A lead frame includes a die paddle, a first lead, a second lead, an extending portion and at least one supporting portion. The first lead includes a first main portion and a first I/O portion opposite to the first main portion. The second lead includes a second main portion and a second I/O portion opposite to the second main portion. The first lead and the second lead surround the die paddle. The extending portion extends from the first main portion of the first lead. The supporting portion is connected to the extending portion.

Abstract: Compounds of formula (I): wherein A1, A2, Ra, Rb, Rc, Rd, R3, R4, R5 and T are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

Abstract: Compound of formula (I): wherein Het, R3, R4, R5, R7, R8, R9, t, p, p?, q, and q? are as defined in the description. Medicinal products containing the same which are useful in treating conditions requiring pro-apoptotic agent.

Abstract: Compounds of formula (1): wherein A1, A2, Ra, Rb, Rc, Rd, R3, R4, R5 and T are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

Abstract: Compound of formula (I): wherein Het, R3, R4, R5, R7, R8, R9, t, p, p?, q, and q? are as defined in the description. Medicinal products containing the same which are useful in treating conditions requiring pro-apoptotic agent.

Abstract: Compound of formula (I): wherein A1, A2, Ra, Rb, Rc, Rd, R3, R4, X, Y and G are as defined in the description, and their use in the manufacture of medicaments.